Company Focus
Teva Pharmaceutical Industries
Latest Teva Pharmaceutical Industries News
Biosimilars
Israel-headquartered Teva Pharmaceutical Industries has announced the launch of Ahzantive (aflibercept), a biosimilar to Eylea, in Europe further strengthening the company’s growing biosimilars portfolio and expanding its presence in ophthalmology. 4 June 2026
Related News
Insights
Company Spotlight
A clinical-stage US biotechnology company developing precisely targeted small molecule kinase inhibitors for cancer, with lead programs in ROS1- and ALK-positive non-small cell lung cancer.
Latest News & Features of interest to Teva Pharmaceutical Industries
Biotechnology
USA-based private clinical stage biopharma AmMax Bio and Switzerland’s Lonza, a leading contract development and manufacturing organization (CDMO), today announced a non-exclusive licensing agreement. 9 June 2026
Pharmaceutical
Swedish CNS specialist AlzeCure Pharma saw it shares rocket 280% to 5.26 kronor by early afternoon, after it revealed it has entered into a collaboration and out-licensing agreement with US pharma major Eli Lilly regarding the global rights to the Alzheimer’s project Alzstatin ACD680. 9 June 2026
Biotechnology
US pharma majors Merck & Co and Gilead Sciences today announced the discontinuation of the Phase III KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab). 9 June 2026
Biotechnology
US life sciences tools company Standard BioTools has agreed to merge with privately-held Treeline Biosciences in an all-stock deal that will turn the business into a clinical-stage biopharma company. 9 June 2026
Biotechnology
Shares in US biotech Tango Therapeutics closed 53% higher on Monday after the company reported early data for its PRMT5 inhibitor vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitor daraxonrasib in pancreatic cancer. 9 June 2026
Biotechnology
US biotech City Therapeutics has raised $99.5 million in a series B financing, giving the young RNA interference specialist more room to advance its pipeline and refine its next-generation RNAi engineering platform. 9 June 2026
Pharmaceutical
UK pharma major GSK revealed it has entered an agreement to acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. 9 June 2026
Pharmaceutical
The USA’s Institute for Clinical and Economic Review (ICER) released a Fina; Evidence Report assessing the comparative clinical effectiveness and value of oveporexton (TAK-861), from Japan’s Takeda Pharmaceutical for narcolepsy type 1. 9 June 2026
Biotechnology
US pharma major Johnson & Johnson has agreed to acquire privately-held Firefly Bio for $1 billion in cash, adding a degrader antibody conjugate (DAC) platform designed to target hard-to-treat solid tumors. 8 June 2026
Biotechnology
Scottish biotech company Bead BioPharma has emerged from stealth after filing its first patent application for a chemistry-based platform designed to improve the performance of antibody-drug conjugates (ADCs). 8 June 2026
Latest In Brief for Teva Pharmaceutical Industries
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze